Welcome to our dedicated page for Collegium Pharmaceutical news (Ticker: COLL), a resource for investors and traders seeking the latest updates and insights on Collegium Pharmaceutical stock.
Collegium Pharmaceutical, Inc. reports developments for a diversified biopharmaceutical business focused on commercial medicines for serious medical conditions. Its recurring news centers on JORNAY PM for ADHD, a neuropsychiatry growth business, and a responsible pain management portfolio that includes BELBUCA, Xtampza ER, Nucynta products and Symproic.
Company updates also cover operating and financial results, investor presentations, real-world data from pain medications, branded ADHD awareness campaigns, capital deployment, credit facilities, material agreements, shareholder voting matters and governance disclosures.
Collegium Pharmaceutical, Inc. reported strong Q1 2024 financial results, including a net revenue of $144.9 million, record Belbuca® revenue of $50.7 million, and GAAP net income of $27.7 million. The company achieved a 5% increase in Adjusted EBITDA, authorized a $35.0 million share repurchase program, and reaffirmed its full-year 2024 guidance. Collegium also announced an authorized generic agreement with Hikma and a leadership transition. Financially, the company showed stable product revenues, reduced GAAP operating expenses, and increased cash reserves.
Collegium Pharmaceutical, Inc. announces CEO transition as Joe Ciaffoni steps down as President and CEO, effective May 24, 2024. Michael Heffernan will serve as Interim President and CEO until a successor is appointed. The Board has initiated the search for a new CEO. Collegium remains financially strong and on track to achieve its 2024 financial guidance.
Collegium Pharmaceutical, Inc. (Nasdaq: COLL) has announced an authorized generic agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER, bolstering the value of the Nucynta Franchise through 2025 and beyond. Collegium will manufacture and supply Hikma with authorized generic products, with Hikma having exclusive rights to sell them in the U.S. Collegium will receive a share of net profits based on the number of generic entrants.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.